Lilly hops on hot molecular glue train with $1.6B+ Magnet deal

Eli Lilly on Friday put more than $1.6 billion on the line in a licensing deal with Boston biotech Magnet Biomedicine, adding another pharma powerhouse to the already-crowded, already-competitive molecular glue space.